zilovertamab,ibrutinib
janssen,oncternal therapeutics,abbvie
['zilovertamab', 'maia', 'cll', ' ibru', 'fil,veral,12', ' pone ', 'lymsm']
congress | #ash22 hun ju lee of shares data from the phase i/ii study of zilovertamab + ibrutinib in #mcl, #cll or #mzl. the combination appears promising, with good response rates and favourable efficacy profiles across the three indications.
#lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm